| Previous Section | Index | Home Page |
28 Jan 2003 : Column 811W—continued
King Edward VII Hospital, Midhurst
Virginia Bottomley: To ask the Secretary of State for Health what (a) volume and (b) type of NHS work was
28 Jan 2003 : Column 812W
undertaken by King Edward VII Hospital, Midhurst, in 2002–03; and if he will make a statement on its future. [92039]
Ms Blears: The information requested is not collected centrally.
Ministers and departmental officials have received a number of representations regarding the situation at the hospital. Discussions with the liquidator are currently ongoing. In view of that, it would not be appropriate for Ministers to comment further, although these discussions will of course focus on the continuing provision of appropriate care for national health service patients.
Maintenance Work
Dr. Evan Harris: To ask the Secretary of State for Health what the cost was of outstanding maintenance work necessary to achieve estate code condition B in the NHS in 2001–02, broken down into (a) fire safety and (b) health and safety costs in (i) England and (ii) each NHS region. [92790]
Mr. Lammy: The cost of outstanding repair and maintenance work necessary to achieve estate code condition B standards in England is commonly termed backlog maintenance costs and are generally broken down into fire safety, health and safety and physical condition elements.
For the year 2001–02 these costs, broken down by the former eight regions and current four Department of Health and Social Care (DHSC) regions are shown in the tables.
| Region | Cost to achieve Physical Condition B | Cost to achieve Statutory Health and Safety Compliance Standard B | Cost to achieve Fire Safety Compliance Standard B | Total backlog |
|---|---|---|---|---|
| Eastern | 269,018 | 17,779 | 21,607 | 308,404 |
| London | 687,774 | 97,676 | 62,937 | 848,387 |
| North West | 311,394 | 38,105 | 23,130 | 372,629 |
| Northern and Yorkshire | 408,689 | 27,279 | 22,540 | 458,507 |
| South East | 375,483 | 56,954 | 25,113 | 457,551 |
| South West | 212,008 | 26,285 | 10,270 | 248,564 |
| Trent | 199,643 | 43,496 | 51,315 | 294,454 |
| West Midlands | 401,518 | 33,834 | 23,632 | 458,983 |
| Total for England | 2,865,526 | 341,409 | 240,544 | 3,447,479 |
| DHSC region | Cost to achieve Physical Condition B | Cost to achieve Statutory Health and Safety Compliance Standard B | Cost to achieve Fire Safety Compliance Standard B | Total backlog |
|---|---|---|---|---|
| London | 687,774 | 97,676 | 62,937 | 848,387 |
| Midlands and Eastern | 857,720 | 90,084 | 90,311 | 1,038,115 |
| North | 796,643 | 72,759 | 53,144 | 922,547 |
| South | 523,388 | 80,890 | 34,151 | 638,429 |
| Total for England | 2,865,526 | 341,409 | 240,544 | 3,447,479 |
28 Jan 2003 : Column 813W
National targets on backlog maintenance set in the NHS Plan are incorporated into the Department of Health priority and planning framework document 2003–06.
Meat (Safety)
Tony Cunningham: To ask the Secretary of State for Health when the Food Standards Agency will issue advice on the safety of eating meat from animals which have been vaccinated against foot and mouth. [92881]
Ms Blears [holding answer 23 January 2003]: I am advised by the Food Standards Agency that the agency issued advice in April 2001 that eating meat, milk or other produce from animals that have been treated with authorised foot and mouth disease vaccines would not have any implications for food safety.
Medical Staff
Chris Grayling: To ask the Secretary of State for Health what right he will have to veto European proposals to introduce the 16 week provision relating to medical staff in the United Kingdom. [93633]
Mr. Hutton: The proposed provision forms part of a draft directive, which is the subject of continuing negotiation. In publishing it, the European Commission stated that its adoption would be by qualified majority insofar as its implementation did not require changes in the law of any member state governing the professions regarding training and conditions of access by natural persons. If that presumption failed, adoption would require unanimity.
28 Jan 2003 : Column 814W
Mental Health Treatment
Tim Loughton: To ask the Secretary of State for Health what guidance has been issued to primary care trusts for the prescription of Aricept, Exelon and Reminyl for patients with mental health problems. [92527]
Jacqui Smith: In January 2001 the National Institute for Clinical Excellence issued guidance to the national health service on the use of Aricept (donepezil), Exelon (rivastigmine) and Reminyl (galantamine) for the treatment of mild to moderate Alzheimer's disease.
Tim Loughton: To ask the Secretary of State for Health how many primary care trusts prescribe (a) Aricept, (b) Exelon and (c) Reminyl. [92528]
Jacqui Smith: Information about the number of primary care trusts in England where these drugs are prescribed is shown in the table.
| April-November 2002 | ||
|---|---|---|
| Number | Percentage | |
| Aricept (Donepezil Hydrochloride) | 304 | 100 |
| Reminyl (Galantamine) | 273 | 90 |
| Exelon (Rivastigmine) | 285 | 94 |
Tim Loughton: To ask the Secretary of State for Health what the current cost to the NHS is of prescribing (a) Aricept, (b) Exelon and (c) Reminyl. [92533]
Jacqui Smith: Information showing the net ingredient cost of prescribing (a) Aricept, (b) Exelon and (c) Reminyl in England is shown in the table.
| Prescribed in GP practices(38) | Prescribed in hospitals(39) | Total NIC(40) | Percentage of NIC of drugs dispensed in the community which were prescribed in hospitals | |
|---|---|---|---|---|
| Aricept (Donepezil Hydrochloride) | ||||
| October-December 2001 | 1,818.3 | 1,137.3 | 2,956.0 | 38 |
| January-March 2002 | 2,046.7 | 1,170.8 | 3,217.6 | 36 |
| April-June 2002 | 2,476.7 | 1,263.3 | 3,740.0 | 34 |
| July-September 2002 | 2,865.0 | 1,405.6 | 4,271.7 | 33 |
| 12 months ending September 2002 | 9,206.8 | 4,977.0 | 14,185.3 | 35 |
| Reminyl (Galantamine) | ||||
| October-December 2001 | 185.5 | 196.8 | 382.5 | 51 |
| January-March 2002 | 240.6 | 215.8 | 456.4 | 47 |
| April-June 2002 | 327.3 | 242.5 | 570.1 | 43 |
| July-September 2002 | 410.3 | 263.5 | 673.9 | 39 |
| 12 months ending September 2002 | 1,163.7 | 918.6 | 2,083.0 | 44 |
| Exelon (Rivastigmine) | ||||
| October-December 2001 | 264.7 | 126.8 | 391.4 | 32 |
| January-March 2002 | 287.5 | 131.0 | 418.5 | 31 |
| April-June 2002 | 325.7 | 138.5 | 464.0 | 30 |
| July-September 2002 | 362.9 | 154.8 | 517.7 | 30 |
| 12 months ending September 2002 | 1,240.8 | 551.1 | 1,791.6 | 31 |
(38) Prescribed in GP practices in England, and dispensed in the community (this can include prescriptions written in England dispensed outside England).
(39) Prescribed in hospitals, and dispensed in the community in England (Also included are prescription written in Wales, Scotland, Northern Ireland and the Isle of Man but dispensed in England).
(40) NIC of all prescription items dispensed in the community in England.
Notes:
Total items may not necessarily equal the sum of 1 and 2, because of the slight difference in geographical cover.
Information about drugs prescribed and dispensed in hospitals is not available.
28 Jan 2003 : Column 815W
Tim Loughton: To ask the Secretary of State for Health how many patients are currently prescribed (a) Aricept, (b) Exelon and (c) Reminyl on the NHS. [92550]
28 Jan 2003 : Column 816W
Jacqui Smith: We do not hold information in the form requested. However, information on the number of prescriptions for dementia drugs dispensed in the community in England is shown in the table.
| Prescribed in GP practices(41) | Prescribed in hospitals(42) | Total items(43) | Percentage of items dispensed in the community which were prescribed in hospitals | |
|---|---|---|---|---|
| Aricept (Donepezil Hydrochloride) | ||||
| October-December 2001 | 22.2 | 8.2 | 30.5 | 27 |
| January-March 2002 | 25.0 | 8.4 | 33.4 | 25 |
| April-June 2002 | 30.2 | 9.3 | 39.4 | 24 |
| July-September 2002 | 35.2 | 9.9 | 45.2 | 22 |
| 12 months ending September 2002 | 112.6 | 35.8 | 148.4 | 24 |
| Reminyl (Galantamine) | ||||
| October-December 2001 | 2.9 | 2.0 | 4.8 | 41 |
| January-March 2002 | 3.7 | 1.8 | 5.6 | 33 |
| April-June 2002 | 4.9 | 2.2 | 7.2 | 31 |
| July-September 2002 | 6.2 | 2.3 | 8.5 | 27 |
| 12 months ending September 2002 | 17.7 | 8.3 | 26.1 | 32 |
| Exelon (Rivastigmine) | ||||
| October-December 2001 | 4.4 | 1.8 | 5.9 | 29 |
| January-March 2002 | 4.8 | 1.8 | 6.3 | 27 |
| April-June 2002 | 5.5 | 1.7 | 7.1 | 24 |
| July-September 2002 | 6.2 | 1.8 | 7.9 | 23 |
| 12 months ending September 2002 | 20.9 | 7.1 | 27.3 | 25 |
(41) Prescribed in GP practices in England, and dispensed in the community (this can include prescriptions written in England dispensed outside England).
(42) Prescribed in hospitals, and dispensed in the community in England (Also included are prescription written in Wales, Scotland, Northern Ireland and the Isle of Man but dispensed in England).
(43) All prescription items dispensed in the community in England.
Notes:
Total items may not necessarily equal the sum of 1 and 2, because of the slight difference in geographical cover.
Information about drugs prescribed and dispensed in hospitals is not available.
| Next Section | Index | Home Page |